MiR-671-5p plays a promising role in restraining osteosarcoma cell characteristics through targeting TUFT1
- PMID: 32115852
- DOI: 10.1002/jbt.22490
MiR-671-5p plays a promising role in restraining osteosarcoma cell characteristics through targeting TUFT1
Abstract
The aim of our study was to explore the roles of miR-671-5p in mediating biological processes of osteosarcoma (OS) cells and clinical implications. On the basis of the OS samples acquired from the GEO database, the expression difference and overall survival analyses of miR-671-5p and TUFT1 were determined. The expression of MiR-671-5p was verified using OS cell lines. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, wound-healing, and Transwell assays were respectively carried out to probe whether miR-671-5p regulated OS cell vitality, migration, and invasion. The expression of miR-671-5p was downregulated in OS tissues and cell lines. High expression of MiR-671-5p blocked OS cell growth, migration, and invasion. TUFT1 was predicted and validated as the target of miR-671-5p in OS cells using in silico analysis and luciferase reporter assays. Forced expression of TUFT1 reversed the suppressive influence of miR-671-5p on cell viability, migration, and invasion of OS cells. Moreover, the low expression of miR-671-5p and the high expression of TUFT1 led to poor prognosis. Taken together, targeting miR-671-5p/TUFT1 may be a promising strategy for treating OS.
Keywords: TUFT1; invasion; miR-671-5p; migration; osteosarcoma; proliferation.
© 2020 Wiley Periodicals, Inc.
Similar articles
-
miR-186-5p Functions as a Tumor Suppressor in Human Osteosarcoma by Targeting FOXK1.Cell Physiol Biochem. 2019;52(3):553-564. doi: 10.33594/000000039. Cell Physiol Biochem. 2019. PMID: 30897321
-
MiR-582-5p inhibits the growth and invasion of osteosarcoma cell by targeting NOVA1.Eur Rev Med Pharmacol Sci. 2020 Nov;24(21):11026-11031. doi: 10.26355/eurrev_202011_23587. Eur Rev Med Pharmacol Sci. 2020. PMID: 33215417
-
miR-624-5p promoted tumorigenesis and metastasis by suppressing hippo signaling through targeting PTPRB in osteosarcoma cells.J Exp Clin Cancer Res. 2019 Dec 11;38(1):488. doi: 10.1186/s13046-019-1491-6. J Exp Clin Cancer Res. 2019. PMID: 31829261 Free PMC article.
-
Knockdown of HCG18 Inhibits Cell Viability, Migration and Invasion in Pediatric Osteosarcoma by Targeting miR-188-5p/FOXC1 Axis.Mol Biotechnol. 2021 Sep;63(9):807-817. doi: 10.1007/s12033-021-00343-6. Epub 2021 May 26. Mol Biotechnol. 2021. PMID: 34041718
-
Mir-34a: a regulatory hub with versatile functions that controls osteosarcoma networks.Cell Cycle. 2022 Oct;21(20):2121-2131. doi: 10.1080/15384101.2022.2087755. Epub 2022 Jun 14. Cell Cycle. 2022. PMID: 35699451 Free PMC article. Review.
Cited by
-
miR-671-5p Upregulation Attenuates Blood-Brain Barrier Disruption in the Ischemia Stroke Model Via the NF-кB/MMP-9 Signaling Pathway.Mol Neurobiol. 2023 Jul;60(7):3824-3838. doi: 10.1007/s12035-023-03318-7. Epub 2023 Mar 22. Mol Neurobiol. 2023. PMID: 36949221
-
microRNA-128-3p inhibits proliferation and accelerates apoptosis of gastric cancer cells via inhibition of TUFT1.World J Surg Oncol. 2023 Feb 17;21(1):47. doi: 10.1186/s12957-023-02906-0. World J Surg Oncol. 2023. PMID: 36797791 Free PMC article.
-
Research progress on the role and mechanism of miR-671 in bone metabolism and bone-related diseases.Front Oncol. 2023 Jan 11;12:1018308. doi: 10.3389/fonc.2022.1018308. eCollection 2022. Front Oncol. 2023. PMID: 36713572 Free PMC article. Review.
-
A review on the role of miR-671 in human disorders.Front Mol Biosci. 2022 Dec 5;9:1077968. doi: 10.3389/fmolb.2022.1077968. eCollection 2022. Front Mol Biosci. 2022. PMID: 36545507 Free PMC article. Review.
-
Association between microRNA 671 polymorphisms and the susceptibility to soft tissue sarcomas in a Chinese population.Front Oncol. 2022 Aug 9;12:960269. doi: 10.3389/fonc.2022.960269. eCollection 2022. Front Oncol. 2022. PMID: 36016604 Free PMC article.
References
REFERENCES
-
- K. B., Jones, Salah, Z., Del Mare, S., Galasso, M., Gaudio, E., Nuovo, G. J., Lovat, F., LeBlanc, K., Palatini, J., Randall, R. L., Volinia, S., Stein, G. S., Croce, C. M., Lian, J. B., R. I. Aqeilan, Cancer Res. 2012, 72, 1865.
-
- M. F. Heymann, H. K. Brown, D. Heymann, Expert Opin. Invest. Drugs 2016, 25, 1265.
-
- L. Ouyang, P. Liu, S. Yang, S. Ye, W. Xu, X. Liu, Med. Oncol. 2013, 30, 340.
-
- D. Hutanu, R. Popescu, H. Stefanescu, L. Pirtea, A. Candea, C. Sarau, O. Boruga, L. Mehdi, I. Ciuca, S. Tanasescu, Biochem. Genet. 2017, 55, 291.
-
- A. Soleimani, M. Khazaei, G. A. Ferns, M. Ryzhikov, A. Avan, S. M. Hassanian, J Cell Physiol 2019, 234, 14574.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
